3Semana
You don't always have to understand the reactions, 1% with the numbers... But still nice
•
33
•
3Semana
@Tool1982 Lots of people have big bags on PFE and are willing to unload so the upside is limited as some want to run away of the stock despite the good news in my opinion
•
11
•3Semana
@Tool1982 Well, I just listened to the whole Earning Call and now I think that the stock traded lower during the today session mainly because of a lack of confidence toward the management and comments made by CEO Albert Bourla towards Activist.
But if I look at the raw numbers, the quarter is quite good and the progression made during the 9 first months of 2024 is great. Pfizer seem for the moment to deliver on it's cost cutting programs and keep on pushing new Phase 1 trials on many sectors. They also seem to be willing to pay down debt ( 2.3 billions $ of maturing + 2.1 billions $ of commercial paper paid in FY2024 so far ) which is a key need for the company considering its high debt level.
Now when it comes to the shareholder value... Yeah the stock have been pretty much dead in the water this years going between 27 and 30$ a share so the results are not there yet. Only true consolation for shareholders this year was the 2.4% dividend raise during Q1 24.
Overall I stay confident in Pfizer to execute their plan and regain shareholders trust, but they will need a blockbuster drug for 2025 in order to definitely convince me that the management did take the right actions.
But if I look at the raw numbers, the quarter is quite good and the progression made during the 9 first months of 2024 is great. Pfizer seem for the moment to deliver on it's cost cutting programs and keep on pushing new Phase 1 trials on many sectors. They also seem to be willing to pay down debt ( 2.3 billions $ of maturing + 2.1 billions $ of commercial paper paid in FY2024 so far ) which is a key need for the company considering its high debt level.
Now when it comes to the shareholder value... Yeah the stock have been pretty much dead in the water this years going between 27 and 30$ a share so the results are not there yet. Only true consolation for shareholders this year was the 2.4% dividend raise during Q1 24.
Overall I stay confident in Pfizer to execute their plan and regain shareholders trust, but they will need a blockbuster drug for 2025 in order to definitely convince me that the management did take the right actions.
•
11
•